



The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models


Supplementary Materials



Supplementary Figure S1: The structure and molecular weight of XL388.



Supplementary Figure S2: MG-63 (A), SaOs-2 (B) cells or primary murine osteoblasts (C) were treated with applied concentration of XL388, rapamycin or RAD001, cells were further cultured for 72 hours, and cell survival was tested by MTT assay. * $p < 0.05$ vs. group "C". # $p < 0.05$ vs. XL388 group (A and B).



Supplementary Figure S3: Expression of listed proteins in listed cells was tested by Western blots. Kinase phosphorylation was quantified (vs. regular kinase).